Linden Capital Partners, a Chicago-based healthcare-focused private equity firm, is exploring a strategic pivot into secondaries investing, according to five industry sources cited by Secondaries Investor. This move would position the $3.5B AUM firm as one of the latest sector-specialist buyout firms entering the secondaries space, which has seen surging interest amid market volatility and fragmented deal flow.

The potential secondaries strategy would prioritize GP-led transactions, where Linden would acquire minority stakes from distressed or underperforming general partners. Sources confirm the firm is actively interviewing candidates with expertise in secondaries to build out this new business line, signaling a deliberate shift from traditional buyout models. This aligns with broader trends among healthcare PE firms seeking alternative growth avenues as deal pipelines face headwinds from regulatory scrutiny and economic uncertainty.

Why secondaries? The strategy offers faster capital deployment and lower upfront risk compared to primary buys, particularly in specialized sectors like healthcare. Linden’s focus on GP-led opportunities suggests a targeted approach to capitalize on inefficiencies in distressed manager portfolios, a niche that has attracted firms like KKR and CVC Capital in recent years. Analysts note this could intensify competition for secondary deals, which surged 40% in Q2 2024.

While Linden has not finalized plans, the mere consideration underscores the accelerating consolidation in secondaries markets. For investors, this signals growing appetite for hybrid strategies blending traditional buyout expertise with opportunistic secondary plays. As one source put it, "This isn’t just about diversification—it’s about survival in a tightening capital environment."